An evaluation of methods to improve the reporting of adherence in a placebo gel trial in Andhra Pradesh, India

AIDS and Behavior

Volumn 17, Issue 6, 2013, Pages 2222-2236

  Abbott, Sharon A ^a   Friedland, Barbara A ^a   Sarna, Avina ^b   Katzen, Lauren L ^a   Rawiel, Ulrike ^a   Srikrishnan, Aylur K ^c   Shalini, C S ^c   Tun, Waimar ^a   Kelly, Christine A ^a   Solomon, Suniti ^c   Mensch, Barbara S ^a  

^a POPULATION COUNCIL   (United States)

^b POPULATION COUNCIL   (India)

^c YRG CARE   (India)

Author keywords

Adherence; Biomarkers; Clinical Trials; Female sex workers; India; Interactive voice response survey (IVRS); Microbicides

Indexed keywords

AGENTS USED INTRAVAGINALLY; ANTIINFECTIVE AGENT; BIOLOGICAL MARKER;

ADOLESCENT; ADULT; ARTICLE; ATTITUDE TO HEALTH; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDIA; INTRAVAGINAL DRUG ADMINISTRATION; MEDICATION COMPLIANCE; MIDDLE AGED; PROSTITUTION; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; STATISTICS; UNSAFE SEX;

ADMINISTRATION, INTRAVAGINAL; ADOLESCENT; ADULT; ANTI-INFECTIVE AGENTS; BIOLOGICAL MARKERS; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HIV INFECTIONS; HUMANS; INDIA; MEDICATION ADHERENCE; MIDDLE AGED; SELF REPORT; SEX WORKERS; UNSAFE SEX; VAGINAL CREAMS, FOAMS, AND JELLIES; YOUNG ADULT;

EID: 84879012198     PISSN: 10907165     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10461-012-0402-z     Document Type: Article

References (74)

1. Heise L. Topical microbicides: new hope for STI/HIV prevention. Takoma Park, MD: Center for Health and Gender Equity (CHANGE); 1999.
2. Elias CJ, Coggins C. Female-controlled methods to prevent sexual transmission to HIV. AIDS. 1996;10(Suppl 3):S43-51.
3. Trussell J, Dominik R. Will microbicide trials yield unbiased estimates of microbicide efficacy? Contraception. 2005;72(6):408-13.
4. Masse B, Boily M-C, Dimitrov D, Desai K. Efficacy dilution in randomized placebo-controlled vaginal microbicide trials. Emerg Themes Epidemiol. 2009;6(1):5.
5. Gordis L. Conceptual and methodologic problems in measuring patient compliance. In: Haynes RB, Taylor DW, Sackett DL, editors. Compliance in health care. Baltimore: Johns Hopkins University Press; 1979. p. 23-45.
6. Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther. 1999;21(6):1074-90; discussion 1073.
7. Burkhart PV, Dunbar-Jacob JM, Rohay JM. Accuracy of children's self-reported adherence to treatment. J Nurs Scholarsh. 2001;33(1):27-32.
8. Trussell J, Grummer-Strawn L. Further analysis of contraceptive failure of the ovulation method. Am J Obstet Gynecol 1991;165(6 Part 2):2054-2059.
9. Trussell J, Grummer-Strawn L. Contraceptive failure of the ovulation method of periodic abstinence. Fam Planning Perspect. 1990;22(2):65-75.
10. Peipert J, Redding CA, Blume J, Allsworth JE, Iannuccillo K, Lozowski F, et al. Design of a stage-matched intervention trial to increase dual method contraceptive use (Projedt PROTECT). Contemp Clin Trials. 2007;28(5):626-37.
11. Montgomery CM, Gafos M, Lees S, Morar NS, Mweemba O, Ssali A, et al. Re-framing microbicide acceptability: findings from the MDP301 trial. Cult Health Sex. 2010;12(6):649-62.
12. Woodsong C, Alleman P. Sexual pleasure, gender power and microbicide acceptability in Zimbabwe and Malawi. AIDS Educ Prev. 2008;20(2):171-87.
13. Tolley EE, Severy LJ. Integrating behavioral and social science research into microbicide clinical trials: challenges and opportunities. Am J Public Health. 2006;96(1):79-83.
14. Wallace A, Thorn M, Maguire RA, Sudol KM, Phillips DM. Assay for establishing whether microbicide applicators have been exposed to the vagina. Sex Transm Dis. 2004;31(8):465-8.
15. Wallace AR, Teitelbaum A, Wan L, Mulima MG, Guichard L, Skiler S, et al. Determining the feasibility of utilizing the microbicide applicator compliance assay for use in clinical trials. Contraception. 2007;76:53-6.
16. Mauck C. Biomarkers for evaluating vaginal microbicides and contraceptives: discovery and early validation. Sex Transm Dis. 2009;36(3 Suppl):S73-5.
17. van de Wijgert J, Jones H, Kilmarx PH. Vaginal microbicide adherence biomarkers should be validated. Lancet. 2009;373(9665):721; author reply 721-2.
18. Mehendale SM, Gupte N, Paranjape RS, Brahme RG, Kohli R, Joglekar N, et al. Declining HIV incidence among patients attending sexually transmited infection clinics in Pune, India. Epidemiol Soc Sci. 2007;45(5):564-9.
19. Kumar R, Jha P, Arora P, Mony P, Bhatia P, Millson P, et al. Trends in HIV-1 in young adults in south India from 2000 to 2004: a prevalence study. Lancet. 2006;367:1164-72.
20. Panchanadeswaran S, Johnson SC, Mayer KH, Srikrishnan AK, Sivaram S, Zelaya CE, et al. Gender differences in the prevalence of sexually transmitted infections and genital symptoms in an urban setting in southern India. Sex Transm Infect. 2006;82(6):491-5.
21. HIV/AIDS South Asia: World Bank; 2007 Available at http://web.worldbank. org/WBSITE/EXTERNAL/COUNTRIES/SOUTHASIAEXT/EXTSAREGTOPHEANUT/EXTSAREGTOPHIVAIDS/ 0,contentMDK:20288516~menuPK:568874~pagePK:34004173~piPK:34003707~theSitePK: 496967,00.html. Accessed Sept 2007.
22. Minnis AM, Steiner MJ, Gallo MF, Warner L, Hobbs MM, van der Straten A, et al. Biomarker validation of reports of recent sexual activity: results of a randomized controlled study in Zimbabwe. Am J Epidemiol. 2009;170(7):918-24.
23. Mauck CK, Doncel GF. Biomarkers of semen in the vagina: applications in clinical trials of contraception and prevention of sexually transmitted pathogens including HIV. Contraception. 2007;75(6):407-19.
24. Ghanem KG, Melendez JH, McNeil-Solis C, Giles JA, Yuenger J, Smith TD, et al. Condom use and vaginal Y-chromosome detection: the specificity of a potential biomarker. Sex Transm Dis. 2007;34(8):620-3.
25. Brotman RM, Melendez JH, Smith TD, Galai N, Zenilman JM. Effect of menses on clearance of Y-chromosome in vaginal fluid: implications for a biomarker of recent sexual activity. Sex Transm Dis. 2010;37(1):1-4.
26. Aho J, Koushik A, Diakite SL, Loua KM, Nguyen VK, Rashed S. Biological validation of self-reported condom use among sex workers in Guinea. AIDS Behav. 2010;14(6):1287-93.
27. Macaluso M, Lawson L, Akers R, Valappil T, Hammond K, Blackwell R, et al. Prostate-specific antigen in vaginal fluid as a biologic marker of condom failure. Contraception. 1999;59(3):195-201.
28. Gallo MF. Self-reported condom use is associated with reduced risk of chlamydia, gonorrhea, and trichomoniasis. Sex Transm Dis. 2007;34(10):829-33.
29. Lundwall A, Bjartell A, Olsson AY, Malm J. Semogelin I and II, the predominant human seminal plasma proteins, are also expressed in non-genital tissues. Mol Hum Reprod. 2002;8(9):805-10.
30. MacQueen KM, Vanichseni S, Kitayaporn D, Lin LS, Buavirat A, Naiwatanakul T, et al. Willingness of infection drug users to participate in an HIV vaccine efficacy trial in Bangkok, Thailand. J Acquir Immune Defic Syndr. 1999;21:243-51.
31. Mensch BS, Hewett PC, Abbott S, Rankin J, Littlefield S, Ahmed K, et al. Assessing the reporting of adherence and sexual activity in a simulated microbicide trial in South Africa: an interview mode experiment using a placebo gel. AIDS Behav. 2011;15(2):407-21.
32. Thomsen S, Gallo M, Ombidi W, Omungo Z, Janowitz B. Randomized controlled trial on whether advance knowledge of prostrate-specific antigen testing improves participant reporting of unprotected sex. Sex Transm Infect. 2007;83(5):419-20.
33. Van Damme L, Wright A, Depraetere K, Rosenstein I, Vandersmissen V, Poulter L, et al. A phase I study of a novel potential intravaginal microbicide, PRO 2000, in healthy sexually inactive women. Sex Transm Infect. 2000;76:126-30.
34. Lacey CJN, Wright A, Weber JN, Profy AT. Measurement of in vivo vaginal microbicide levels of PRO 2000 achieved in a human safety study. AIDS 2006; 20(7).
35. Mauck C, Rosenberg Z, Van Damme L. Recommendations for the clinical development of topical microbicides: an update. AIDS. 2001;15(7):857-68.
36. Katzen LL, Fernández-Romero JA, Sarna A, Murugavel KG, Gawarecki D, Zydowsky TM, et al. Validation of a dye stain assay for vaginally inserted hydroxyethylcellulose-filled microbicide applicators. Sex Transm Dis. 2011;38(11):1050-5. doi: 10.1097/OLQ.0b013e31822e6160.
37. Skoler-Karpoff S, Ramjee G, Ahmed K, Altini L, Plagianos MG, Friedland B, et al. Efficacy of carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9654):1977-87.
38. Haberer J, Kiwanuka J, Nansera D, Wilson I, Bangsberg D. Challenges in using mobile phones for collection of antiretroviral therapy adherence data in a resource-limited setting. AIDS Behav. 2010;14(6):1294-301.
39. De Costa A, Shet A, Kumarasam N, Ashorn P, Eriksson B, Bogg L, et al. Design of a randomized trial to evaluate the influence of mobile phone reminders on adherence to first line antiretroviral treatment in South India - the HIVIND study protocol. BMC Med Res Methodol 2010;10(25).
40. Mbuagbaw L, Thabane L, Ongolo-Zogo P, Lang T. The challenges and opportunities of conducting a clinical trial in a low resource setting: the case of the Cameroon mobile phone SMS (CAMPS) trial, an investigator initiated trial. In: Trials; 2011.
41. Rodrigues R, Antony ASJ, Sidney K, Arumugam K, Krishnamurthy S, D'Souza G, et al. Supporting adherence to antiretroviral therapy with mobile phone reminders: results from a cohort in South India. In: PLoS One; 2012.
42. Allen CF, Lees SS, Desmond NA, Der G, Chiduo B, Hambleton I, et al. Validity of coital diaries in a feasibility study for the microbicides development programme trial among women at high risk of HIV/AIDS in Mwanza. Tanzania. Sex Transm Infect. 2007;83:490-7.
43. Ferguson AG, Morris CN, Kariuki CW. Using diaries to measure parameters of transactional sex: An example from the Trans-Africa highway in Kenya. Cult Health Sex. 2006;8(2):175-85.
44. Ramjee G, Weber AE, Morar NS. Recording sexual behavior: comparison of recall questionnaires with a coital diary. Sex Transm Dis. 1999;26(7):374-80.
45. McLaws M, Oldenburg B, Ross M, Cooper D. Sexual behaviour in AIDS-related research: reliability and validity of recall and diary measures. J Sex Res. 1990;27(2):265-81.
46. Miller L, Hays R. Measuring adherence to antiretroviral medications in clinical trials. HIV Clin Trials. 2000;1(1):36-46.
47. Hays MA, Irsula B, McMullen SL, Feldblum PJ. A comparison of three daily coital diary designs and a phone-in regimen. Contraception 2001;63(3):159-166(8) .
48. Weiler K, Christ A, Woodworth G, Weiler R, Weiler J. Quality of patient-reported outcome data captured using paper and interactive voice response diaries in an allergic rhinitis study: is electronic data capture really better? Ann Allergy Asthma Immunol. 2004;92(3):335-9.
49. Corkrey R, Parkinson L. Interactive voice response: review of studies 1989-2000. Behav Res Methods Instrum Comput. 2002;34(3):342-53.
50. Searles JS, Perrine MW, Mundt JC, Helzer JE. Self-report of drinking using touch-tone telephone: extending the limits of reliable daily contact. J Stud Alcohol. 1995;56(4):375-82.
51. Piette JD. Interactive voice response systems in the diagnosis and management of chronic disease. Am J Manag Care. 2000;6(7):817-27.
52. Schroder K, Johnson C. Interactive voice response technology to measure HIV-related behavior. Curr HIV/AIDS Rep. 2009;6(4):210-6.
53. Mensch BS, Friedland BA, Abbott SA, Katzen LL, Tun W, Kelly CA, et al. Characteristics of female sex workers in southern India willing and unwilling to participate in a placebo gel trial. AIDS Behav. 2012. doi: 10.1007/s10461-012- 0259-1.
54. Tun W, Katzen L, Abbott S, Srikrishnan AK, Kelly C, Sarna A, et al. Using a 2-stage strategy with respondent-driven sampling to recruit a hard-to-reach population for a placebo microbicide gel clinical trial in Nellore, Andhra Pradesh (India). (Submitted 2011).
55. Herold B. Personal communication. 2012.
56. Sarna AS, Friedland BA, Srikrishnan AK, Katzen LL, Tun W, Abbott SA, et al. Sexually transmitted infections and reproductive health morbidity among a cohort of female sex workers screened for a microbicide feasibility study in Nellore, India In preparation. 2012.
57. Tien D, Schnaare RL, Kang F, Cohil G, McCormick TJ, Moench TR, et al. In vitro and in vivo characterization of a potential universal placebo designed for use in vaginal microbicide clinical trials. AIDS Res Hum Retroviruses. 2005;21(10):845-53.
58. Schwartz JL, Mauck C, Lai JJ, Creinin MD, Brache V, Ballagh SA, et al. Fourteen-day safety and acceptability study of 6% cellulose sulfate gel: a randomized double-blind phase I safety study. Contraception. 2006;74(2):133-40.
59. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010;329(5996):1168-74.
60. Abdool Karim SS, Richardson BA, Ramjee G, Hoffman IF, Chirenje ZM, Taha T, et al. Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS. 2011.
61. McCormack S, Ramjee G, Kamali A, Rees H, Crook AM, Gafos M, et al. PRO2000 vaginal gel for prevention of HIV-1 infection (microbicides development programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet. 2010;376(9749):1329-37.
62. Van Damme L, Govinden R, Mirembe FM, Guedou F, Solomon S, Becker ML, et al. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med. 2008;359(5):463-72.
63. Coetzee N, Blanchard K, Ellertson C, Hoosen AA, Friedland B. Acceptability and feasibility of Micralax applicators and of methyl cellulose gel placebo for large-scale clinical trials of vaginal microbicides. AIDS. 2001;15(14):1837-42.
64. Nunn A, McCormack S, Crook A, Pool R, Rutterford C, Hayes R. Microbicides development programme: design of a phase III trial to measure the efficacy of the vaginal microbicide PRO 2000/5 for HIV prevention. Trials 2009;10(99).
65. Gallo M, Behets F, Steiner M, Hobbs M, Hoke T, Van Damme K, et al. Prostate-specific antigen to ascertain reliability of self-reported coital exposure to semen. Sex Transm Dis. 2006;33(8):476-9.
66. Mensch BS. The validity of self-reported data on unprotected sex: practical challenges to successful RCT execution: population selection, condom use, reliability of self-reported data. Washington, DC: Hormonal Contraception-HIV Acquisition Risk Meeting; 2011.
67. Kelly CA, Hewett PC, Mensch BS, Nsobya S, Kalibala S, Nyegenye W, et al. Assessing the validity of sexual behaviour reporting among young women in Kampala, Uganda: evidence from a randomized interview mode experiment with biological data. (Submitted 2012).
68. Thomsen SC, Gallo MF, Ombidi W, Omungo Z, Janowitz B, Hawken M, et al. Randomised controlled trial on whether advance knowledge of prostate-specific antigen testing improves participant reporting of unprotected sex. Sex Transm Infect. 2007;83:419-20.
69. Lauritsen K. Symptom recording in a randomised clinical trial: paper diaries vs. electronic or telephone data capture. Control Clin Trials. 2004;25(6):585-97.
70. Stone AA, Shiffman S, Schwartz JE, Broderick JE, Hufford MR. Patient compliance with paper and electronic diaries. Control Clin Trials. 2003;24(2):182-99.
71. Tourangeau R, Smith TW. Asking sensitive questions: the impact of data collection mode, question format, and question context. Public Opin Q. 1996;60(2):275-304.
72. Tourangeau R, Smith TW. Collection sensitive information with different modes of data collection. In: Couper MPl, Reginal P. Baker, Jelke Bethlehem, Cynthia Z.F. Clark, Jean Martin, William L. Nicholls II, James M. O'Reilly, editor. Computer assisted survey information collection. New York: Wiley; 1998. p. 431-453.
73. Austin MN, Rabe LK, Hillier SL. Limitations of the dye-based method for determining vaginal applicator use in microbicide trials. Sex Transm Dis. 2009;36(6):368-71.
74. Mauck CK, Schwartz JL. Dyeing to know: the use of vaginal applicator staining and other techniques to assess adherence to product use in microbicide trials. Sex Transm Dis. 2012;39(9):713-5.